HROW•benzinga•
William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy
Summary
Harrow licensed U.S. rights to FDA-approved BYQLOVI for post-surgical eye pain and adds momentum to its branded ophthalmic drug strategy.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by benzinga